Key Laboratory of Beijing for Identification and Safety Evaluation of Chinese Medicine, Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing 100700, China.
Key Laboratory of Beijing for Identification and Safety Evaluation of Chinese Medicine, Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing 100700, China.
J Pharm Biomed Anal. 2022 Sep 20;219:114951. doi: 10.1016/j.jpba.2022.114951. Epub 2022 Jul 19.
The compositions of traditional Chinese medicines are extremely complex,as a result, exploring consistent quality is demanded and challenging. Quality consistency of products obtained from the same manufacturer has received little attention. The strategy of quality consistency evaluation (QCE) has been proposed as a novel method for quality control of Traditional Chinese Medicine Patent Prescription (TCMPP). This study aimed to establish a comprehensive QCE strategy for Compound Danshen Tablet (CDT). High Performance Liquid Chromatography-Diode Array Detector and Gas Chromatography-Mass Spectrometry were separately applied to determinate the content of seven and two index components, which representing the quality actuality of different raw medicines. The dissolution test was designed to obtain the dissolution ratios of CDT samples. QCE can provide the intra-batch content consistency difference (P), inter-batch content consistency difference (P), and dissolution ratio consistency difference (P) values. The consistency of CDT samples from 15 different manufacturers (75 batches) was evaluated by principal component analysis (PCA), which showed that the total content (nine index components) of the 75 batches of samples obtained from 15 manufacturers ranged from 22.11 to 38.45 mg·tablet. The dissolution ratios ranged from 74.8% to 116.4%. The P values of 15 manufacturers ranged from 2.4% to 12.2%, and the P (11.1-45.1%) values were higher than the P values. The P values reflecting the various dissolution ratios in vitro ranged from 8.1% to 57.5%. The three consistency factors were ranked by PCA, and products of the 15 manufacturers were classified into three categories. The P, P, and P values provided a comprehensive and effective approach for monitoring the quality consistency of CDT and can serve as an example of QCE for other TCMPP.
中药的成分非常复杂,因此需要探索一致的质量标准,这是一项具有挑战性的任务。同一制造商生产的产品的质量一致性问题尚未得到充分关注。质量一致性评价(QCE)策略已被提出作为中药专利处方(TCMPP)质量控制的一种新方法。本研究旨在建立一种全面的复方丹参片(CDT)QCE 策略。高效液相色谱-二极管阵列检测器和气相色谱-质谱法分别用于测定七种和两种指标成分的含量,以代表不同原料药的质量现状。设计了溶出度试验以获得 CDT 样品的溶出度比值。QCE 可以提供批内含量一致性差异(P)、批间含量一致性差异(P)和溶出度一致性差异(P)值。通过主成分分析(PCA)对来自 15 家不同制造商(75 批)的 CDT 样品的一致性进行了评估,结果表明,来自 15 家制造商的 75 批样品的总含量(9 种指标成分)范围为 22.11-38.45 mg·片。溶出度比值范围为 74.8%-116.4%。15 家制造商的 P 值范围为 2.4%-12.2%,P(11.1-45.1%)值高于 P 值。反映体外不同溶出度比值的 P 值范围为 8.1%-57.5%。通过 PCA 对这三个一致性因素进行了排序,并将 15 家制造商的产品分为三类。P、P 和 P 值为监测 CDT 的质量一致性提供了一种全面有效的方法,可为其他 TCMPP 的 QCE 提供范例。